At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Selumetinib +1 moredrug
Likely dose
Selumetinib 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD6244 in Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Selumetinib for Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma. Completed, enrolled 37 participants across 9 sites.
Detailed Summary
This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionMar 2012
TodayJul 2026
First PostedMar 11, 2010
Enrollment StartMar 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.3 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Selumetinibdrug
AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles